8-K: Relmada Therapeutics Secures Nasdaq Capital Market Transfer and Listing Extension

Relmada Therapeutics, Inc. announced its transfer to the Nasdaq Capital Market and received a 180-day extension to regain compliance with the $1 minimum bid price requirement.

Summary

• Relmada Therapeutics, Inc. (the "Company") previously received a Nasdaq notification on January 21, 2025, for failing to maintain a minimum bid price of $1 per share for 30 consecutive business days, ending January 17, 2025.
• The initial 180-day compliance period for the minimum bid price rule ended on July 21, 2025.
• On July 22, 2025, Nasdaq approved the Company's application to transfer its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market.
• The transfer of the Company's securities to the Nasdaq Capital Market will be effective at the opening of business on July 24, 2025.
• Nasdaq also granted a 180-day extension, until January 19, 2026 (the "Compliance Period"), for the Company to regain compliance with the minimum bid price rule (Nasdaq Listing Rule 5550(a)(2)).
• To regain compliance, the Company's common stock must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to the expiration of the Compliance Period.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the company avoided immediate delisting and received an extension, the underlying issue of failing to maintain the minimum bid price persists, and there's no guarantee of future compliance. The transfer to the Nasdaq Capital Market is a downgrade from the Nasdaq Global Select Market.

Positives

• Nasdaq approved the Company's application to transfer its listing to the Nasdaq Capital Market, avoiding immediate delisting from the Nasdaq Global Select Market.
• The Company received a 180-day extension, until January 19, 2026, to regain compliance with the minimum bid price requirement.
• Management intends to actively monitor the bid price and take all reasonable measures to regain compliance.

Negatives

• The Company failed to maintain the minimum $1 bid price requirement for continued listing on the Nasdaq Global Select Market.
• There is no assurance that the Company will be able to regain or maintain compliance with the applicable continued listing standards.

Risks

• Inability to regain compliance with the minimum bid price rule for the Nasdaq Capital Market.
• Failure to maintain compliance with other applicable continued listing standards set forth in the Nasdaq Listing Rules.
• Factors outlined under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-K and latest Form 10-Q, which may be updated in other SEC filings.

Future Outlook

The Company intends to actively monitor its bid price during the extended compliance period and plans to take all reasonable measures available to regain compliance with the requirements for continued listing on the Nasdaq Capital Market. However, there is no assurance that the Company will be able to regain or maintain compliance with the applicable listing standards.

Management Comments

• The Company intends to actively monitor the Companys bid price during the Compliance Period and intends to take all reasonable measures available to regain compliance with the requirements for continued listing on the Nasdaq Capital Market.

Industry Context

This event reflects a common challenge faced by smaller biotechnology or pharmaceutical companies, particularly those in clinical development stages, which may experience stock price volatility and struggle to maintain exchange listing requirements. Transferring to the Nasdaq Capital Market is a standard procedure for companies that fail to meet the more stringent requirements of the Nasdaq Global Select Market, providing a grace period to rectify the issue while maintaining public trading.

Stakeholder Impact

• Shareholders: Face continued uncertainty regarding the Company's listing status and potential delisting if compliance is not regained. The transfer to the Nasdaq Capital Market might affect liquidity or investor perception.

Next Steps

• The Company's securities will be transferred to the Nasdaq Capital Market at the opening of business on July 24, 2025.
• The Company must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days prior to January 19, 2026, to regain compliance.
• Management intends to actively monitor the bid price and take all reasonable measures to regain compliance.

Key Dates

Recommendation

The company has received a crucial extension and a transfer to a less stringent market, which temporarily alleviates the immediate delisting threat. This provides a window for the company to address its share price. However, the underlying issue of failing to meet the minimum bid price remains unresolved, and there's no guarantee of future compliance. Investors should hold to see if the company can successfully regain compliance within the extended period, as failure to do so would lead to further negative consequences, while success could stabilize the stock. A 'buy' is premature given the ongoing risk, and a 'sell' is not immediately warranted as the company has been granted a reprieve.

Keywords

RELMADA THERAPEUTICS, RLMD, Nasdaq, Listing Compliance, Minimum Bid Price, Nasdaq Capital Market, Delisting Risk, SEC Filing, 8-K, Stock Exchange